Worldwide Healthcare Trust’s Post

𝑩𝒓𝒆𝒂𝒌𝒊𝒏𝒈 𝑵𝒆𝒘𝒔 📢: 𝑹𝒆𝒔𝒆𝒂𝒓𝒄𝒉 𝑻𝒆𝒂𝒎 𝑫𝒊𝒔𝒄𝒐𝒗𝒆𝒓𝒔 𝑮𝒓𝒐𝒖𝒏𝒅𝒃𝒓𝒆𝒂𝒌𝒊𝒏𝒈 𝑩𝒊𝒐𝒎𝒂𝒓𝒌𝒆𝒓 𝒇𝒐𝒓 𝑳𝒊𝒗𝒆𝒓 𝑪𝒊𝒓𝒓𝒉𝒐𝒔𝒊𝒔 𝑫𝒊𝒂𝒈𝒏𝒐𝒔𝒊𝒔! 🧬 Exciting news in the liver cirrhosis market! A groundbreaking therapy has emerged, offering hope 🌟 for patients worldwide. This innovative treatment, backed by pioneering research 🔬, promises to revolutionize patient care 🏥 and transform the landscape of liver disease management. With novel biomarkers and advanced protocols, this breakthrough marks a significant leap forward 🚀 in medical science, bringing renewed optimism to those affected by liver cirrhosis. 𝙁𝙤𝙧𝙚 𝙈𝙤𝙧𝙚 𝙄𝙣𝙛𝙤: https://bit.ly/3St8mQZ Top Key Players: F. Hoffmann-La Roche Ltd GlaxoSmithKline Consumer Healthcare, L.P. Intercept Pharmaceuticals Johnson Controls Gilead Sciences. Merck Group Bristol Myers Squibb #MedicalAdvancements 🌈

We're excited to have Annick de Bruin, Chief Research and Insights Officer, Center for Information and Study on Clinical Research Participation (CISCRP), USA sharing the results from CISCRP's 2023 Perceptions & Insights Study this September at Patient Perspectives and Partnering! This study found that “Information critical to participant decision-making includes knowing potential risks and benefits, study purpose, how the investigational treatment is believed to work, as well as knowing involved procedures, potential out-of-pocket costs, physical clinic location, and study duration”. Join Annick in Amsterdam to learn more about these crucial study findings, as well as experts from Novartis, Regeneron, use MY data, Sanofi, GSK, Boehringer Ingelheim, James Lind Care, FibroFlutters, Genentech, FDA, braintust and many more. And gain leading advice that will help you address these pivotal considerations early, improve patient engagement and maximise your trial outcomes. 📅 Download the agenda to learn more: https://lnkd.in/eJwWvV3N 👉 Register today: https://lnkd.in/eGH7Jqi5 #PatientPerspectives24 #PatientEngagement #ClinicalTrials #ClinicalResearch #PatientPartnerships

Good brand leaders do the right thing even when it's hard. That's what the co-CEOs, Josh Cohen and Justin Klee, of pharmaceuticals company Amylyx did last month. Amylyx is dedicated to developing treatments for neurodegenerative diseases like ALS (Lou Gehrig's disease) and Alzheimer's. In early clinical trials, their drug Relyvrio had shown to keep nerve cells alive in patients with ALS, so the FDA approved it for use in 2022. It was early for such an approval, but Cohen and Klee made a public promise to do what was right for patients based on the results of a larger Phase 3 study to come. Fast forward two years: That Phase 3 study showed the drug was no better than a placebo for helping people with ALS. So Cohen and Klee honored their promise, and took Relyvrio off the market to new patients. Existing patients who believe they are benefiting from Relyvrio can now have the drug for free. This move cost Amylyx hundreds of billions in annual revenue. Its stock price fell by 80% in hours, and the company's market value fell by more than $1B. The voluntary act shocked skeptics used to a me-first attitude in the pharmaceutical industry. The promise wasn't legally binding, and the FDA almost never takes a drug off the market once it's been approved. Cohen told NPR: "As hard as it is for us, it's much harder for them. And we've made a commitment at every point to act with integrity, to do the right thing, to follow the science. And that's what we tried to do here as well." One of the reasons that Amylyx was able to make this decision was because they purposefully stayed independent — part of their strategy to ensure they could uphold their values. I'm sure there are plenty of people who have issues with Amylyx. But if more CEOs acted like Cohen and Klee did — played the long game, building trust and brand loyalty with customers by acting transparently, with integrity, responsibility, and customers at the heart of their mission — the world would be a better place. Of course, this is easier said than done. How can we encourage more brand leaders to act with similar mission-driven transparency and integrity? #leadership #integrity #brandbuilding #brandstrategy

Download the newest Healthcare Monthly Report from TM Capital. It covers the latest industry M&A deal activity and news, as well as trends in valuation. #TMCapital #ExtraordinaryOutcomes #ClientCare #Healthcare #BioTech #Pharma #LifeScience #Diagnostics #MedicalDevices #MergersandAcquisitions #InvestmentBank #FinancialAdvisor #Atlanta #NewYork #Boston

With new trends and policy implementations in 2024, #pharma executives are strategically and optimistically approaching the year ahead.    At #JPM24, CEO Mark Litton, Ph.D. shared his thoughts with Meagan Parrish on how Athira is adapting to these new policies, including the #IRA.   Read his thoughts in the new PharmaVoice trend piece here: https://bit.ly/3S0nVPP  

Tomorrow, October 2nd, G&L experts will sit on the 'Maximize Your Drug Asset Value & Commercial Success' panel at Biocom California's offices in San Diego. Dr. Steven Hildemann, MD, PhD, R&D Physician at G&L, will be joined by industry experts including Krishna Allamneni, Executive Vice President, Chief Development Officer at Concarlo Therapeutics, Inc., and @Dr. Michael J. Nowak, Managing Partner, Nowak Ventures, LLC. With a focus on integrating regulatory, clinical, and commercial expertise, this discussion will help you develop novel strategies that set your asset apart. If you're in discovery, pre-clinical, or mid-phase clinical development, this is a must-attend event for gaining insights on increasing valuation at key inflection points. ***Please note, this event is now taking place at Biocom California's offices in San Diego - 10996 Torreyana Rd, San Diego, California 92121*** #HealthcareAdvisors #RegulatoryAffairs #QualityAssurance #ThoughtLeadership #Biopharma

Explore the realm of biosimilars with Dr. Christian K Schneider! Discover the latest insights on biosimilar access and affordability in the insightful blog published on ACRP - Association of Clinical Research Professionals. Key takeaways: 🌟 Biosimilars hold immense potential for enhancing patient access to vital therapies. 📈 Tangible savings and increased acceptance of biosimilars are reshaping the industry landscape. 🤝 Collaboration between industry and regulators is pivotal for navigating regulatory pathways effectively. 🧠 Educating stakeholders on biosimilar testing protocols is critical for fostering support and understanding. Read more now: 🔗 https://lnkd.in/gntRWz7f #PharmaLex #Biosimilars #ClinicalResearch #Affordability

Our experts Clément François, Shrividya Iyer, Ph.D, and Eros Papademetriou will be attending the ISPOR annual conference in Atlanta this week! We’re excited to share insights from work by Scott Briggs, Thomas Marder, Clement, and Shrividya on implications of the Medicare Price Negotiation provisions under the Inflation Reduction Act. Our research delves into the potential shifts in biopharmaceutical strategies, focusing on investment priorities, drug development, and lifecycle management. We predict significant impacts on how therapies are brought to market, emphasizing the need for robust evidence to support pricing negotiations, especially for the elderly patient population. For a deeper dive into our findings, feel free to connect with us or visit our poster #HPR97 at the conference: https://lnkd.in/dD5XD_ep ISPOR—The Professional Society for Health Economics and Outcomes Research #ISPOR2024 #HEOR #MarketAccess #biopharma #MedicarePriceNegotiation #InflationReductionAct

Explore the realm of biosimilars with Dr. Christian K Schneider! Discover the latest insights on biosimilar access and affordability in the insightful blog published on ACRP - Association of Clinical Research Professionals. Key takeaways: 🌟 Biosimilars hold immense potential for enhancing patient access to vital therapies. 📈 Tangible savings and increased acceptance of biosimilars are reshaping the industry landscape. 🤝 Collaboration between industry and regulators is pivotal for navigating regulatory pathways effectively. 🧠 Educating stakeholders on biosimilar testing protocols is critical for fostering support and understanding. Read more now: 🔗 https://lnkd.in/dnbdJ-Yc #PharmaLex #Biosimilars #ClinicalResearch #Affordability

We are thrilled to announce that Market Access Today is officially partnering with the World Evidence, Pricing and Access Congress 2025! Scheduled for March 5-6 at the RAI Congress Centre in Amsterdam, this event is set to be Europe's largest congress in market access, pricing, and evidence, featuring over 250 speakers and welcoming more than 1,500 attendees from the pharmaceutical, biotech, and payer sectors. As we expand the dialogue in healthcare, Market Access Today is proud to stand alongside esteemed solution providers like Valid Insight (part of the Bioscript Group), RxData, Lifescience Dynamics Limited, and Parexel. Together, we'll explore core topics such as Market Access and Pricing, Rare Diseases, and HTA/Payer dynamics, while delving into the latest trends in reimbursement, payment models, and HEOR. We're immensely grateful for the warm congratulations and flattering messages from the event representatives and our community. Your support energizes our commitment to driving innovation and leadership in healthcare. Let's make a transformative impact at the World Evidence, Pricing and Access Congress 2025. Join us as we help shape the future of healthcare. For more information and to register, please visit World Evidence, Pricing and Access Congress 2025: https://lnkd.in/dnbYK3Ft #EPAConf #heor #health #pricing #reimbursement #healtheconomics #healthpolicy #marketaccess #pharmaceuticals #rarediseases #payer